U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H22N2O4
Molecular Weight 318.3676
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMBERACETAM

SMILES

CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)CC2=CC=CC=C2

InChI

InChIKey=PJNSMUBMSNAEEN-AWEZNQCLSA-N
InChI=1S/C17H22N2O4/c1-2-23-16(21)12-18-17(22)14-9-6-10-19(14)15(20)11-13-7-4-3-5-8-13/h3-5,7-8,14H,2,6,9-12H2,1H3,(H,18,22)/t14-/m0/s1

HIDE SMILES / InChI
Molecular Formula C17H22N2O4
Molecular Weight 318.3676
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12596521 https://examine.com/supplements/noopept/

Noopept (DVD-111) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. Noopept was patented by Russian-based pharmaceutical company JSC LEKKO Pharmaceuticals in the 1996. Research shows Noopept has similar effects, but works differently than other nootropics in the racetam-family. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, U.S. Patent 5,439,930 issued 8/8/1995. Noopept exhibits a combined neuroprotector effect both in vitro and in vivo. Noopept decreases the extent of necrotic damage caused by photoinduced thrombosis of cortical blood vessels. It was established that the neuroprotector effect of noopept is related to its action upon the well-known "triad", whereby the drug reduces neurotoxic effects of excess extracellular calcium, glutamate, and free radicals. Two additional components of the neuroprotector action of noopept are related to the antiinflammatory and antithrombotic activity.

CNS Activity

CNS Active
4002
Curator's Comment: Noopept is very bioavailable and easily crosses the blood-brain barrier.

Originator

CJSC LEKKO Pharmaceuticals
1
Curator's Comment: Noopept was patented by Russian-based pharmaceutical company JSC LEKKO Pharmaceuticals in the 1996.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 1.21 µM [IC50]
Modulator
846
Brain-derived neurotrophic factor
2
Target ID: P23560|||Q9BYY7
Gene ID: 627.0
Gene Symbol: BDNF
Target Organism: Homo sapiens (Human)
Activator
1447
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Noopept

Approved Use

Noopept used for the treatment of patients of different age groups of adults and elderly patients suffering from cognitive impairment and emotional lability of various origins. In particular, the drug can be assigned Noopept after craniocerebral injury and coma, as well as patients with cerebral circulatory insufficiency of various etiologies including encephalopathy and asthenic disorders. Noopept can be assigned to improve the cognitive functions of memory, concentration and learning ability in patients with increased physical, intellectual and emotional loads.
Doses

Doses

DosePopulationAdverse events​
20 mg 2 times / day multiple, oral
Recommended|Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
Other AEs: Irritability, Sleep disturbance...
Other AEs:
Irritability (grade 1, 9.7%)
Sleep disturbance (grade 1-2, 16.1%)
Increased blood pressure (grade 2-3, 9.7%)
Headache (grade 1, 3.2%)
Chest pain (grade 1, 3.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
AEs

AEs

AESignificanceDosePopulation
Chest pain grade 1, 3.2%
20 mg 2 times / day multiple, oral
Recommended|Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
Headache grade 1, 3.2%
20 mg 2 times / day multiple, oral
Recommended|Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
Irritability grade 1, 9.7%
20 mg 2 times / day multiple, oral
Recommended|Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
Sleep disturbance grade 1-2, 16.1%
20 mg 2 times / day multiple, oral
Recommended|Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
Increased blood pressure grade 2-3, 9.7%
20 mg 2 times / day multiple, oral
Recommended|Highest studied dose
Dose: 20 mg, 2 times / day
Route: oral
Route: multiple
Dose: 20 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/19234797/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2438
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
2052
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
2497
 inconclusive [IC50 37.9083 uM]
CYP2D6
2546
 no
CYP3A4
2633
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 no
PubMed

PubMed

TitleDatePubMed
The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model.
2007-08
Patents

Patents

2119496
1
US2011166063
1
US2016022828
1

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Noopept is primarily water-soluble nootropic, but won’t easily dissolve in water or juice. So it may help if you take it with a meal containing healthy fats. Or with a tablespoon of extra virgin, expeller cold-pressed coconut or olive oil. Or other similar healthy fat to ensure quick absorption. For even quicker absorption you can use Noopept sublingually. Let the tablet or powder dissolve under your tongue so it can go straight into your blood-stream, and into your brain. Bypassing your digestive system completely.
Recommended Noopept dosage is 10 – 30 mg per day. Noopept is sold in tablet, capsule and powder form. Tablets and capsules are usually 10 mg each.
Route of Administration: Oral
In Vitro Use Guide
Noopept (GVS-111) significantly increased neuronal survival after H(2)O(2)-treatment displaying a dose-dependent neuroprotective activity from 10nM to 100 microM, and an IC(50) value of 1.21 /-0.07 microM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 20:55:35 GMT 2025
Edited
by admin
on Mon Mar 31 20:55:35 GMT 2025
Record UNII
4QBJ98683M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMBERACETAM
INN  
Official Name English
NOOPEPT
WHO-DD  
Preferred Name English
Omberacetam [WHO-DD]
Common Name English
GVS-111
Code English
omberacetam [INN]
Common Name English
N-PHENYLACETYL-L-PROLYLGLYCINE ETHYL ESTER
Systematic Name English
J759.455K
Code English
Classification Tree Code System Code
DSLD 3380 (Number of products:17)
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
Code System Code Type Description
CAS
157115-85-0
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
WIKIPEDIA
N-Phenylacetyl-L-prolylglycine ethyl ester
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
SMS_ID
100000154968
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
PUBCHEM
180496
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID80166214
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
INN
10682
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
EVMPD
SUB128773
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
FDA UNII
4QBJ98683M
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
NCI_THESAURUS
C166777
Created by admin on Mon Mar 31 20:55:35 GMT 2025 , Edited by admin on Mon Mar 31 20:55:35 GMT 2025
PRIMARY
Related Record Type Details
Structure of CYCLO(PROLYLGLYCYL)
METABOLITE ACTIVE -> PARENT
Related Record Type Details
Structure of OMBERACETAM
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966